These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

123 related items for PubMed ID: 9467039

  • 1. Rationale for treatment design: biochemical modulation of 5-fluorouracil by leucovorin.
    Rustum YM, Cao S, Zhang Z.
    Cancer J Sci Am; 1998; 4(1):12-8. PubMed ID: 9467039
    [Abstract] [Full Text] [Related]

  • 2. Activity of high dose 24 hour 5-fluorouracil infusion plus L-leucovorin in advanced colorectal cancer.
    Nobile MT, Barzacch MC, Sanguineti O, Chiara S, Gozza A, Vincenti M, Lavarello A, Cognein P, Lionetto R, Percivale PL, Bertoglio S, Murolo C, Esposito M, Vannozzi MO, Rosso R.
    Anticancer Res; 1998; 18(1B):517-21. PubMed ID: 9568171
    [Abstract] [Full Text] [Related]

  • 3. Interleukin 15 protects against toxicity and potentiates antitumor activity of 5-fluorouracil alone and in combination with leucovorin in rats bearing colorectal cancer.
    Cao S, Troutt AB, Rustum YM.
    Cancer Res; 1998 Apr 15; 58(8):1695-9. PubMed ID: 9563485
    [Abstract] [Full Text] [Related]

  • 4. Systemic treatment options in advanced colorectal cancer: perspectives on combination 5-fluorouracil plus leucovorin.
    Grem JL.
    Semin Oncol; 1997 Oct 15; 24(5 Suppl 18):S18-8-S18-18. PubMed ID: 9420016
    [Abstract] [Full Text] [Related]

  • 5. [Chronotherapy with high dose carboplatin, 5-fluorouracil and leucovorin in advanced colorectal carcinoma].
    Popov I, Jelić S, Radosavljević D, Nikolić-Tomasević A.
    Srp Arh Celok Lek; 1998 Oct 15; 126(9-10):355-61. PubMed ID: 9863407
    [Abstract] [Full Text] [Related]

  • 6. Phase I/II study of oxaliplatin with weekly bolus fluorouracil and high-dose leucovorin (ROX) as first-line therapy for patients with colorectal cancer.
    Yamada Y, Ohtsu A, Boku N, Miyata Y, Shimada Y, Doi T, Muro K, Muto M, Hamaguchi T, Mera K, Yano T, Tanigawara Y, Shirao K.
    Jpn J Clin Oncol; 2006 Apr 15; 36(4):218-23. PubMed ID: 16684860
    [Abstract] [Full Text] [Related]

  • 7. Etoposide added to weekly leucovorin (LV)/5-fluorouracil (5-FU) in LV/5-FU pre-treated patients with advanced colorectal cancer.
    Tsavaris N, Kosmas C, Gennatas K, Vadiaka M, Paliaros P, Dimitrakopoulos A, Diamantis T, Tsipras H, Papastratis G.
    Med Sci Monit; 2002 Sep 15; 8(9):PI65-9. PubMed ID: 12218954
    [Abstract] [Full Text] [Related]

  • 8. 5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer.
    Sobrero A, Guglielmi A, Cirillo M, Recaldin E, Frassineti GL, Aschele C, Ravaioli A, Testore P, Caroti C, Gallo L, Pessi MA, Cortesi E, Turci D, Grossi F, Labianca R.
    Br J Cancer; 2001 Apr 20; 84(8):1023-8. PubMed ID: 11308248
    [Abstract] [Full Text] [Related]

  • 9. Biomodulation of 5-fluorouracil with antifolates.
    Bertino JR.
    Semin Oncol; 1997 Oct 20; 24(5 Suppl 18):S18-52-S18-56. PubMed ID: 9420021
    [Abstract] [Full Text] [Related]

  • 10. Phase II study of weekly oxaliplatin and high-dose infusional 5-fluorouracil plus leucovorin in pretreated patients with metastatic colorectal cancer.
    Chiara S, Nobile MT, Gozza A, Taveggia P, Heouaine A, Pastrone I, Percivale PL, Lionetto R, Sanguineti O, Rosso R.
    Anticancer Res; 2004 Oct 20; 24(1):355-60. PubMed ID: 15015621
    [Abstract] [Full Text] [Related]

  • 11. Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial.
    Cascinu S, Labianca R, Barone C, Santoro A, Carnaghi C, Cassano A, Beretta GD, Catalano V, Bertetto O, Barni S, Frontini L, Aitini E, Rota S, Torri V, Floriani I, Italian Group for the Study of Digestive Tract Cancer, Pozzo C, Rimassa L, Mosconi S, Giordani P, Ardizzoia A, Foa P, Rabbi C, Chiara S, Gasparini G, Nardi M, Mansutti M, Arnoldi E, Piazza E, Cortesi E, Pucci F, Silva RR, Sobrero A, Ravaioli A.
    J Natl Cancer Inst; 2007 Apr 18; 99(8):601-7. PubMed ID: 17440161
    [Abstract] [Full Text] [Related]

  • 12. [The biochemical modulation of 5-fluorouracil by leucovorin].
    Borner M, Brunner K.
    Schweiz Med Wochenschr; 1991 Aug 17; 121(33):1149-56. PubMed ID: 1925442
    [Abstract] [Full Text] [Related]

  • 13. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
    Kemeny N, Garay CA, Gurtler J, Hochster H, Kennedy P, Benson A, Brandt DS, Polikoff J, Wertheim M, Shumaker G, Hallman D, Burger B, Gupta S.
    J Clin Oncol; 2004 Dec 01; 22(23):4753-61. PubMed ID: 15570076
    [Abstract] [Full Text] [Related]

  • 14. A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil.
    Hsu CH, Cheng AL, Hsu C, Yang CH, Lu YS, Lin CC, Bu CF, Yeh KH.
    Anticancer Res; 2002 Dec 01; 22(6B):3621-7. PubMed ID: 12552966
    [Abstract] [Full Text] [Related]

  • 15. Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer.
    Hochster H, Chachoua A, Speyer J, Escalon J, Zeleniuch-Jacquotte A, Muggia F.
    J Clin Oncol; 2003 Jul 15; 21(14):2703-7. PubMed ID: 12860947
    [Abstract] [Full Text] [Related]

  • 16. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803.
    Saltz LB, Niedzwiecki D, Hollis D, Goldberg RM, Hantel A, Thomas JP, Fields AL, Mayer RJ.
    J Clin Oncol; 2007 Aug 10; 25(23):3456-61. PubMed ID: 17687149
    [Abstract] [Full Text] [Related]

  • 17. UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer.
    Hoff PM, Pazdur R, Benner SE, Canetta R.
    Anticancer Drugs; 1998 Jul 10; 9(6):479-90. PubMed ID: 9877235
    [Abstract] [Full Text] [Related]

  • 18. Phase I and pharmacokinetic study of weekly 5-fluorouracil administered with granulocyte-macrophage colony-stimulating factor and high-dose leucovorin: a potential role for growth factor as mucosal protectant.
    Meropol NJ, Rustum YM, Creaven PJ, Blumenson LE, Frank C.
    Cancer Invest; 1999 Jul 10; 17(1):1-9. PubMed ID: 10999043
    [Abstract] [Full Text] [Related]

  • 19. Biochemical modulation of combined radiation and 5-fluorouracil treatment of murine tumors by d,l-leucovorin.
    Kovacs CJ, Dainer PM, Evans MJ, Nyce J.
    Anticancer Res; 1991 Jul 10; 11(2):905-9. PubMed ID: 2064349
    [Abstract] [Full Text] [Related]

  • 20. [Leucovorin and 5-FU for advanced gastrointestinal cancer].
    Sasaki T, Maeda Y, Kobayashi T.
    Gan To Kagaku Ryoho; 1999 Mar 10; 26(4):440-6. PubMed ID: 10097740
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.